Intracranial administration of CAR-T cells targeting IL13Rα2, a monomeric high-affinity receptor for IL-13 found to be overexpressed in glioblastomas [216], improves T-cell persistence and antitumor efficacy against glioblastoma [217, 218]. This evidence concerns the gene IL13 and glioblastoma.